Free tool · No account

Clinical trials for lung cancer

Lung cancer has more targeted trials than almost any other cancer, many keyed to a specific mutation (EGFR, ALK, KRAS, ROS1, and others). Knowing the tumor's biomarker often surfaces the most relevant studies.

1,293 recruiting trials. Showing a sample.

  • recruitingPhase 2NCT06667622

    Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

    To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.

    Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical SciencesFull details on ClinicalTrials.gov →
  • recruitingPhase 2NCT07323056

    Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

    This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer...

    Sponsored by Shanghai Pulmonary Hospital, Shanghai, ChinaFull details on ClinicalTrials.gov →
  • recruitingPhase 2NCT06623656

    Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

    The goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC). Before surgery to remove their lung cancer, partici...

    Sponsored by Weill Medical College of Cornell UniversityFull details on ClinicalTrials.gov →
  • recruitingPhase 1NCT05753722

    A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Sponsored by Incendia TherapeuticsFull details on ClinicalTrials.gov →
  • recruitingNCT06718972

    A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China

    This is a retrospective and prospective study planned to include NSCLC patients with Leptomeningeal metastasis (LM) and treated with antitumor therapy after 2018, from multiple centers such as the First Affiliated Hospital of Guangzhou Medical University, Guangdong Sanjiu Brai...

    Sponsored by Guangzhou Medical UniversityFull details on ClinicalTrials.gov →
  • recruitingPhase 1, Phase 2NCT07148128

    Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

    This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

    Sponsored by Auricula Biosciences Inc.Full details on ClinicalTrials.gov →
  • recruitingPhase 1, Phase 2NCT04895709

    A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340...

    Sponsored by Bristol-Myers SquibbFull details on ClinicalTrials.gov →
  • recruitingPhase 1, Phase 2NCT06448572

    EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

    As treatment options are limited following progression on anti PD-(L)1 and platinum-based chemotherapy, we propose this trial for patients who have failed to respond or have shown intolerance to standard therapies or for whom no appropriate therapies are known to provide clini...

    Sponsored by University Hospital, LilleFull details on ClinicalTrials.gov →
  • recruitingNANCT07216209

    The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer

    There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic mak...

    Sponsored by University of ArizonaFull details on ClinicalTrials.gov →
  • recruitingPhase 1, Phase 2NCT05269381

    Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

    This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is design...

Data from ClinicalTrials.gov, retrieved 2026-07-13. These are trials worth asking your care team about, not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.

Refine for your situation

Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.

Whatever you have: the diagnosis, a mutation if you know it, age, where you live.

Trials for other conditions

What we will never do with your records

This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.

We won't sell your data.
Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
We won't train AI models on your records.
Anthropic (whose Claude model powers KeptWell) is contractually prohibited from training on anything we send them, under a signed Business Associate Agreement.
We won't lock you in.
You can export everything in your circle as a ZIP at any time. Cancellation is one click.

Read the full data practices →

Common questions

Is this lung cancer trial finder really free?
Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
Does showing up here mean the patient qualifies?
No. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
How current is this list?
The trials come directly from ClinicalTrials.gov and are refreshed daily. Each result links to the full, live study record, and the finder above always runs a fresh search when you use it.
What should I do with a trial that looks promising?
Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.

Found trials worth discussing? Keep them next to the records.

The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.

Get started

No password. We'll email you a sign-in link — it works whether you're new here or already have an account.